Home
Resources
Publications
Gentiopicroside Inhibits RANKL-induced Osteoclastogenesis by Regulating NF-κB and JNK Signaling Pathways

Gentiopicroside Inhibits RANKL-induced Osteoclastogenesis by Regulating NF-κB and JNK Signaling Pathways

Fangqing Chen, Lin Xie, Ran Kang, Rongrong Deng, Zhipeng Xi, Daoxi Sun, Jin Zhu, Liming Wang

Biomed Pharmacother. 2018 Apr;100:142-146.

PMID: 29428661

Abstract:

Gentiopicroside, a main active component from the traditional Chinese herb medicine Gentiana manshurica Kitag, has been shown to possess anti-arthritis effect. However, the molecular mechanism of gentiopicroside on the osteoclast formation remains unclear. The present study was designed to investigate the effects and mechanisms of gentiopicroside on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis. The results showed that pre-treatment with gentiopicroside significantly inhibited RANKL-induced osteoclast formation from mouse bone marrow macrophages (BMMs). In addition, we observed that gentiopicroside efficiently suppressed osteoclastogenesis-related marker genes expression in RANKL-stimulated BMMs. Mechanistically, gentiopicroside suppressed RANKL-induced the activation of JNK and NF-κB signaling pathways in BMMs. Taken together, the present study demonstrated that gentiopicroside inhibits RANKL-induced osteoclastogenesis through the inactivation of JNK and NF-κB signaling pathways. Thus, gentiopicroside may be a promising agent for the treatment of osteoporosis.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP20831769	Gentiopicroside		20831-76-9	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: